PYXS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
-100.0%
11.0M
0
Cost of Revenue
0
0
0
-100.0%
2.4M
0
Gross Profit
0
0
0
-100.0%
8.7M
0
Operating Expenses
20.5M
-21.0%
26.0M
+6.7%
24.4M
-9.6%
26.9M
+14.9%
23.5M
R&D
16.6M
+3.1%
16.1M
-19.6%
20.0M
-8.0%
21.7M
+21.9%
17.8M
SG&A
4.0M
-60.1%
9.9M
+126.9%
4.4M
-16.4%
5.2M
-7.4%
5.7M
Operating Income
-20523000
+21.0%
-25990000
-6.7%
-24360000
-33.2%
-18295000
+22.0%
-23461000
EBITDA
-20224000
+21.3%
-25689000
-7.5%
-23901000
-55.2%
-15398000
+32.9%
-22934000
Net Income
-19984000
+21.2%
-25346000
-8.9%
-23272000
-28.5%
-18106000
+17.7%
-22003000
EPS (Basic)
$-0.24
+40.0%
$-0.40
-8.1%
$-0.37
-27.6%
$-0.29
+17.1%
$-0.35
EPS (Diluted)
$-0.24
+40.0%
$-0.40
-8.1%
$-0.37
-27.6%
$-0.29
+17.1%
$-0.35
Shares (Diluted)
83.5M
+30.5%
64.0M
+0.8%
63.5M
+0.7%
63.0M
+0.8%
62.6M
Pyxis Oncology (PYXS) — Financials